AfghanistanTuberculosis profile
Population  2017 36 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 10 (6–15) 29 (17–43)
Mortality (HIV+TB only) 0.063 (<0.01–0.17) 0.18 (0.03–0.47)
Incidence  (includes HIV+TB) 67 (43–96) 189 (122–270)
Incidence (HIV+TB only) 0.21 (0.14–0.3) 0.59 (0.38–0.85)
Incidence (MDR/RR-TB)** 3.2 (1.5–5.5) 9 (4.3–15)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 3.6 (1.4–5.8) 31 (12–50) 34 (15–53)
Males 4 (1.5–6.4) 29 (11–47) 33 (15–51)
Total 7.5 (4.3–11) 60 (34–86) 67 (43–96)
TB case notifications, 2017  
Total cases notified 47 406
Total new and relapse 46 640
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 48%
          - % pulmonary 73%
          - % bacteriologically confirmed among pulmonary 61%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 70% (49–110)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.16 (0.08–0.26)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 7 <1%
          - on antiretroviral therapy 3 43%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1 700
(1 000–2 300)
Estimated % of TB cases with MDR/RR-TB 3.7% (2–5.9) 21% (15–27)  
% notified tested for rifampicin resistance 6% 95% 5 251
MDR/RR-TB cases tested for resistance to second-line drugs   279
Laboratory-confirmed cases MDR/RR-TB: 279, XDR-TB: 5
Patients started on treatment **** MDR/RR-TB: 198, XDR-TB: 5
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 93% 40 287
Previously treated cases, excluding relapse, registered in 2016 90% 568
HIV-positive TB cases registered in 2016 0% 1
MDR/RR-TB cases started on second-line treatment in 2015 64% 83
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 4%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
> 100%
TB financing, 2018  
National TB budget (US$ millions) 11
Funding source: 5% domestic, 93% international, 2% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-01-23 Data: www.who.int/tb/data